{
  "name": "Amgen",
  "slug": "amgen",
  "ticker": "AMGN",
  "fetched_at": "2026-02-12T12:41:37.825025+00:00",
  "news": [
    {
      "title": "Stratos Wealth Partners LTD. Has $8.83 Million Stake in Amgen Inc. $AMGN - MarketBeat",
      "link": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOYzNheGlNOHRDenRqd3BfblUxdU56cFcwN2ZLUktSWU5ETnRLQi1zcDdkbkJGSXRpM0c0R2F4dGJ2Z2VfX1VBTDJ0cHFZTVpEV1RjUUVScjRMalVXS2hkZXVFWDhaSWozeGVqVFlrbzVsWlk3anNNVlZpX1pXckNkVHNxbjhnaml0ZlZlcG9yNGpuNkNOQTZFVDF6cGdsN3BsaVB1Sks0NUFFdVd5dHBvYzNuTVBtNHpqNVRaQjhmMFFSSUE3Ykhv?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMixwFBVV95cUxOYzNheGlNOHRDenRqd3BfblUxdU56cFcwN2ZLUktSWU5ETnRLQi1zcDdkbkJGSXRpM0c0R2F4dGJ2Z2VfX1VBTDJ0cHFZTVpEV1RjUUVScjRMalVXS2hkZXVFWDhaSWozeGVqVFlrbzVsWlk3anNNVlZpX1pXckNkVHNxbjhnaml0ZlZlcG9yNGpuNkNOQTZFVDF6cGdsN3BsaVB1Sks0NUFFdVd5dHBvYzNuTVBtNHpqNVRaQjhmMFFSSUE3Ykhv?oc=5\" target=\"_blank\">Stratos Wealth Partners LTD. Has $8.83 Million Stake in Amgen Inc. $AMGN</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">MarketBeat</font>",
      "published": "2026-02-12T12:36:18+00:00",
      "source": "MarketBeat"
    },
    {
      "title": "Highlights from Amgen's 2025 Fourth Quarter and Full Year Earnings Report - Amgen",
      "link": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNa1A1XzhsX21GQmMxVWNQQWlKSmFsN0d2Zk1saTI4al9sZW1WODJmMFZpMWpRQ1QzbE1qSjZieTU4WEFMblBSeEQxekZjSkZFQm00MmNnVnNhTmlpdmgzYVF3emZBZmptQ2dJVGJnWlh1NFE5TlFreE80SWxjdF8tSUp5enRVenFBMVZrc2lfbnRFLXJDaUV6SzlrcVU1M292TW9kVlFsajBmU0lhdElR?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMirwFBVV95cUxNa1A1XzhsX21GQmMxVWNQQWlKSmFsN0d2Zk1saTI4al9sZW1WODJmMFZpMWpRQ1QzbE1qSjZieTU4WEFMblBSeEQxekZjSkZFQm00MmNnVnNhTmlpdmgzYVF3emZBZmptQ2dJVGJnWlh1NFE5TlFreE80SWxjdF8tSUp5enRVenFBMVZrc2lfbnRFLXJDaUV6SzlrcVU1M292TW9kVlFsajBmU0lhdElR?oc=5\" target=\"_blank\">Highlights from Amgen's 2025 Fourth Quarter and Full Year Earnings Report</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Amgen</font>",
      "published": "2026-02-03T08:00:00+00:00",
      "source": "Amgen"
    },
    {
      "title": "AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS - PR Newswire",
      "link": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPbGlPdTREbHB3UXJRZlFydG9zTGQyMnlkeTcwNmpGaTlQdnhiTDJXN1A5SG9VR2R2VWx1cGVpVmJneU9VVzhwVUo1NFc5REswbXV2S2x5cWxrd2dKV19nOTFmNGlERnhTRXhFMVNmWUhVVll0WEFjR2hSajR4T252LXlSTk9rbFhfMHM1NEJiRVFPVHZReUNQbzNKVWZKbTZOV1haQkZNNFZibHZueVRkMHoxLURNVG04bWZ4dllB?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMivgFBVV95cUxPbGlPdTREbHB3UXJRZlFydG9zTGQyMnlkeTcwNmpGaTlQdnhiTDJXN1A5SG9VR2R2VWx1cGVpVmJneU9VVzhwVUo1NFc5REswbXV2S2x5cWxrd2dKV19nOTFmNGlERnhTRXhFMVNmWUhVVll0WEFjR2hSajR4T252LXlSTk9rbFhfMHM1NEJiRVFPVHZReUNQbzNKVWZKbTZOV1haQkZNNFZibHZueVRkMHoxLURNVG04bWZ4dllB?oc=5\" target=\"_blank\">AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">PR Newswire</font>",
      "published": "2026-02-03T21:01:00+00:00",
      "source": "PR Newswire"
    },
    {
      "title": "Amgen Defends Tavneos Benefit-Risk Profile Following FDA Withdrawal Request - Medical Professionals Reference",
      "link": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNRS1GUXNRaS1jZzMwS0JhcmJTT3JYc01KdjlwbERzU1pQclhqTVpWZHQ4V091V1VfU2N0N0FSV1RBUFkwM0tqS25JUjY3Ukx3ZG9abGQwYXRtckI2Q215ZzBLZkpuTlliVE1GMHRUM1ZsamxOR0FJVmc3WkZ5cFVlR2pTV0RCRkRRdVdfTG95MTZxemFHX2pWQmZFeWN4TjB5eHVpZg?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMipAFBVV95cUxNRS1GUXNRaS1jZzMwS0JhcmJTT3JYc01KdjlwbERzU1pQclhqTVpWZHQ4V091V1VfU2N0N0FSV1RBUFkwM0tqS25JUjY3Ukx3ZG9abGQwYXRtckI2Q215ZzBLZkpuTlliVE1GMHRUM1ZsamxOR0FJVmc3WkZ5cFVlR2pTV0RCRkRRdVdfTG95MTZxemFHX2pWQmZFeWN4TjB5eHVpZg?oc=5\" target=\"_blank\">Amgen Defends Tavneos Benefit-Risk Profile Following FDA Withdrawal Request</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Medical Professionals Reference</font>",
      "published": "2026-02-04T05:00:00+00:00",
      "source": "Medical Professionals Reference"
    },
    {
      "title": "Amgen, Merck share losses contribute to Dow's 200-point drop - MSN",
      "link": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNWmpyMVIxNWdBblduakVWQXlUSmVrcG45MXFObXdTR0JfNHUyUUJGckx5dzFvOTZKWm50QWU5ZUppRkJpamFOd1huT0lrc1BDbWNVLVlORXRianBnU3FyNjM4cmRjRlRmYUk3U0UyWUl3MTMwM2pZV3RkekV1TVFrcnlnN0M3WHBwUUxod1N1T1NGcThmMi14SFg5ZExaRUV2TDFKYS1DNUZMaEpqNGw4dg?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMisAFBVV95cUxNWmpyMVIxNWdBblduakVWQXlUSmVrcG45MXFObXdTR0JfNHUyUUJGckx5dzFvOTZKWm50QWU5ZUppRkJpamFOd1huT0lrc1BDbWNVLVlORXRianBnU3FyNjM4cmRjRlRmYUk3U0UyWUl3MTMwM2pZV3RkekV1TVFrcnlnN0M3WHBwUUxod1N1T1NGcThmMi14SFg5ZExaRUV2TDFKYS1DNUZMaEpqNGw4dg?oc=5\" target=\"_blank\">Amgen, Merck share losses contribute to Dow's 200-point drop</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">MSN</font>",
      "published": "2026-02-09T15:30:05+00:00",
      "source": "MSN"
    },
    {
      "title": "Just Two Days Till Amgen Inc. (NASDAQ:AMGN) Will Be Trading Ex-Dividend - Yahoo Finance",
      "link": "https://news.google.com/rss/articles/CBMiekFVX3lxTE5zeTJybl9jdS1rQjdNTXRyaWtWWG9lc2VqMWloNVB1SjdHZndPdVo2OGtVX1ROUFQyY1RMRW13QXV2c1VJSGs5MHhudzJGaGdMTzR5V2lCSW1QdHBMalRUZWs1dDVkU0huYXN1aUZMUHVwR21Sdzc1V1FB?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiekFVX3lxTE5zeTJybl9jdS1rQjdNTXRyaWtWWG9lc2VqMWloNVB1SjdHZndPdVo2OGtVX1ROUFQyY1RMRW13QXV2c1VJSGs5MHhudzJGaGdMTzR5V2lCSW1QdHBMalRUZWs1dDVkU0huYXN1aUZMUHVwR21Sdzc1V1FB?oc=5\" target=\"_blank\">Just Two Days Till Amgen Inc. (NASDAQ:AMGN) Will Be Trading Ex-Dividend</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Yahoo Finance</font>",
      "published": "2026-02-10T13:15:56+00:00",
      "source": "Yahoo Finance"
    },
    {
      "title": "Ex-Dividend Reminder: Cencora, Amgen and Oppenheimer Holdings - Nasdaq",
      "link": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOVWpYOWFQbzlzMmlFMXh5YVNndFM5VkRaSU02TFluN1JoVmpXLWJrTm9rSDRxLTVnWUV5NnVNSTVKOGlmOXc1NzBaUU1qVzRYTkZQRXMyU0ZfT2pqMUZHUk1PckJBVEFTT1hQdmNhVHhOREtxVVI0ek5FUks4cFAxbkcxR25ObXZUMWctSHo1ZGRMX1B2eXc?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMilgFBVV95cUxOVWpYOWFQbzlzMmlFMXh5YVNndFM5VkRaSU02TFluN1JoVmpXLWJrTm9rSDRxLTVnWUV5NnVNSTVKOGlmOXc1NzBaUU1qVzRYTkZQRXMyU0ZfT2pqMUZHUk1PckJBVEFTT1hQdmNhVHhOREtxVVI0ek5FUks4cFAxbkcxR25ObXZUMWctSHo1ZGRMX1B2eXc?oc=5\" target=\"_blank\">Ex-Dividend Reminder: Cencora, Amgen and Oppenheimer Holdings</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Nasdaq</font>",
      "published": "2026-02-11T15:29:00+00:00",
      "source": "Nasdaq"
    },
    {
      "title": "Fierce Pharma Asia—Amgen, Kyowa's OX40 divorce; Roche's RNAi deal; Daiichi's ADC cull - Fierce Pharma",
      "link": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPZmhFMXhES2VlNXoxdzduZ2pSVkNiRHZmbHZ5R2xGbk9BNDFUZW9vWlNIUTFXUm1zV0JiRkZsa19FbjhOMDhaaXU3aDBsZUp1VU1rRm5JLXVmTjl1YnpvVVFJd2NPaXY1UUFZNEhFT2M4c2hWb1FCZkJKSUVhQUhYLW1RSUs5ZEdzVHFGUnpJUVZ3V1VWb19LTw?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMimAFBVV95cUxPZmhFMXhES2VlNXoxdzduZ2pSVkNiRHZmbHZ5R2xGbk9BNDFUZW9vWlNIUTFXUm1zV0JiRkZsa19FbjhOMDhaaXU3aDBsZUp1VU1rRm5JLXVmTjl1YnpvVVFJd2NPaXY1UUFZNEhFT2M4c2hWb1FCZkJKSUVhQUhYLW1RSUs5ZEdzVHFGUnpJUVZ3V1VWb19LTw?oc=5\" target=\"_blank\">Fierce Pharma Asia—Amgen, Kyowa's OX40 divorce; Roche's RNAi deal; Daiichi's ADC cull</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Fierce Pharma</font>",
      "published": "2026-02-06T14:48:00+00:00",
      "source": "Fierce Pharma"
    }
  ],
  "product_launches": [
    {
      "title": "Amgen: Solid New-Product Uptake Offset by Legacy Erosion and Execution Risks, Warranting a Hold Rating - TipRanks",
      "link": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxNOGRMMXF5YlJsZk83RlJqN3ozY1VjSUlkYnpXX05zZmZCWnRoRHNrTk9IdGVYczVZVk9WTkw0MjNKYmkySWZXOUdDdGFXZWRrRjR6U0VSbmtJbkx6NkQ1bkQycGxEWDlZRVdSTzJidFBabTZLOWxkWnI0WktQMXRNX1lCS04xMmFhV3lrV1BDbGRmRlVhSnBfV1BaMmoyc3hTV3lZOTBRX08tRnRuX0hKTkplc05sN1Q2enYxSDE4X2ZkcFVVU1lENks1VUJHWFZzY2tfOUIxaFBEa1dnRkQw?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMi3wFBVV95cUxNOGRMMXF5YlJsZk83RlJqN3ozY1VjSUlkYnpXX05zZmZCWnRoRHNrTk9IdGVYczVZVk9WTkw0MjNKYmkySWZXOUdDdGFXZWRrRjR6U0VSbmtJbkx6NkQ1bkQycGxEWDlZRVdSTzJidFBabTZLOWxkWnI0WktQMXRNX1lCS04xMmFhV3lrV1BDbGRmRlVhSnBfV1BaMmoyc3hTV3lZOTBRX08tRnRuX0hKTkplc05sN1Q2enYxSDE4X2ZkcFVVU1lENks1VUJHWFZzY2tfOUIxaFBEa1dnRkQw?oc=5\" target=\"_blank\">Amgen: Solid New-Product Uptake Offset by Legacy Erosion and Execution Risks, Warranting a Hold Rating</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">TipRanks</font>",
      "published": "2026-02-04T03:18:16+00:00",
      "source": "TipRanks"
    },
    {
      "title": "Amgen, Kyowa Kirin Bolster Safety Profile for Atopic Dermatitis Hopeful - BioSpace",
      "link": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQVEJYNkQ0cURCVTNSd1VIbU1JLWtmblBqXzNDZnp6SVBBcWpGcm5zNWdaUFZwdjN4aGR4TnJoYm9PMWk2STRNdmdKMjRKU2pQVURtamRpUDBja3ZhYk1ONHJRemdtdkpVRHJ3SXBESkdyNG1hMW1ZQW4wb0xpYmMxY0E5RkRyVERkaS1FczJlUmZmbVZRN2VWenB5czdkeFg4eG5jNkZqQm9RU3FaMjl6dl9R?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMisgFBVV95cUxQVEJYNkQ0cURCVTNSd1VIbU1JLWtmblBqXzNDZnp6SVBBcWpGcm5zNWdaUFZwdjN4aGR4TnJoYm9PMWk2STRNdmdKMjRKU2pQVURtamRpUDBja3ZhYk1ONHJRemdtdkpVRHJ3SXBESkdyNG1hMW1ZQW4wb0xpYmMxY0E5RkRyVERkaS1FczJlUmZmbVZRN2VWenB5czdkeFg4eG5jNkZqQm9RU3FaMjl6dl9R?oc=5\" target=\"_blank\">Amgen, Kyowa Kirin Bolster Safety Profile for Atopic Dermatitis Hopeful</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">BioSpace</font>",
      "published": "2025-09-10T07:00:00+00:00",
      "source": "BioSpace"
    },
    {
      "title": "A Look at Amgen’s (AMGN) Valuation as Repatha Scores Major Trial Win and Direct Sales Launch Spurs Optimism - Yahoo Finance",
      "link": "https://news.google.com/rss/articles/CBMihgFBVV95cUxObWpGcHFxUm1WbnhhdFJUOW1kcjlGamhOQTdxdnVqWVRmQkxzNzdYd0poQk96QVByUENRMHhxQlFhVXctWGhjSWw4bjIzMXoxdFhLaVhpU0xMbnltTjhBejY4X1lQOWJuRENDNjVTbWxRRjZMMERRT0RVLVdETjhUcVljeTM3QQ?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMihgFBVV95cUxObWpGcHFxUm1WbnhhdFJUOW1kcjlGamhOQTdxdnVqWVRmQkxzNzdYd0poQk96QVByUENRMHhxQlFhVXctWGhjSWw4bjIzMXoxdFhLaVhpU0xMbnltTjhBejY4X1lQOWJuRENDNjVTbWxRRjZMMERRT0RVLVdETjhUcVljeTM3QQ?oc=5\" target=\"_blank\">A Look at Amgen’s (AMGN) Valuation as Repatha Scores Major Trial Win and Direct Sales Launch Spurs Optimism</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Yahoo Finance</font>",
      "published": "2025-10-16T07:00:00+00:00",
      "source": "Yahoo Finance"
    },
    {
      "title": "3 major patent losses this year — and a key strategy to fill the gaps - PharmaVoice",
      "link": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPNGpDZTgwdDRLOFozTU9HVGVzWWpkS1dXSEd4X1c0RzVVdktmbzUwVVhWSW01X3BkbGl5c084anVWeHVkX1FEU1pEMm13ZW91WlBwNE5CQVVmYURaaEFOREx0dk1fTTJyT01lYW1ZVXBOV2ZXTTdFamNYc2FVbTAyazJOeEVnNkszUXphcjI5blNXSV9wZ0tmcThR?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMimgFBVV95cUxPNGpDZTgwdDRLOFozTU9HVGVzWWpkS1dXSEd4X1c0RzVVdktmbzUwVVhWSW01X3BkbGl5c084anVWeHVkX1FEU1pEMm13ZW91WlBwNE5CQVVmYURaaEFOREx0dk1fTTJyT01lYW1ZVXBOV2ZXTTdFamNYc2FVbTAyazJOeEVnNkszUXphcjI5blNXSV9wZ0tmcThR?oc=5\" target=\"_blank\">3 major patent losses this year — and a key strategy to fill the gaps</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">PharmaVoice</font>",
      "published": "2025-07-21T07:00:00+00:00",
      "source": "PharmaVoice"
    },
    {
      "title": "Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns - Seeking Alpha",
      "link": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNNldFcDdyVUNrRFhsN2JMUDZuakRJNDN5R0JBNzFfbXNuaGVLVTRubVhsV3l2eEk4MGR2X2xLcXVON3NHVVZOVjZvZHNzdHBsTGVNZEFJaEp2WGRxUnNYdng4TS1yaWNrd1g5bW5tcnNvZUh1QzlleW96akRZUG1tNGRKLXdqdmg5TUdudlpielVzcHd2VUpYa3pfWkJjX0lESEJDc3BET1hFWGtreWdqNEdkNlMtT2dncThfMVVuOA?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMivwFBVV95cUxNNldFcDdyVUNrRFhsN2JMUDZuakRJNDN5R0JBNzFfbXNuaGVLVTRubVhsV3l2eEk4MGR2X2xLcXVON3NHVVZOVjZvZHNzdHBsTGVNZEFJaEp2WGRxUnNYdng4TS1yaWNrd1g5bW5tcnNvZUh1QzlleW96akRZUG1tNGRKLXdqdmg5TUdudlpielVzcHd2VUpYa3pfWkJjX0lESEJDc3BET1hFWGtreWdqNEdkNlMtT2dncThfMVVuOA?oc=5\" target=\"_blank\">Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Seeking Alpha</font>",
      "published": "2025-07-15T07:00:00+00:00",
      "source": "Seeking Alpha"
    }
  ],
  "stock": {
    "ticker": "AMGN",
    "currency": "USD",
    "latest": {
      "date": "2026-02-11",
      "close": 366.5799865722656
    },
    "history": [
      {
        "date": "2026-02-03",
        "close": 338.5899963378906
      },
      {
        "date": "2026-02-04",
        "close": 366.20001220703125
      },
      {
        "date": "2026-02-05",
        "close": 367.79998779296875
      },
      {
        "date": "2026-02-06",
        "close": 384.32000732421875
      },
      {
        "date": "2026-02-09",
        "close": 375.82000732421875
      },
      {
        "date": "2026-02-10",
        "close": 364.6499938964844
      },
      {
        "date": "2026-02-11",
        "close": 366.5799865722656
      }
    ],
    "name": "Amgen Inc."
  }
}